Nanotechnology Now - Press Release: VG Energy's Algal Biofuel Enhancement Technology Spotlighted at National Conference: Chief Scientist to Discuss Recent Scientific Breakthroughs at NanoEnergy Conference Focusing on Commercialization of Technologies

Home > Press > VG Energy's Algal Biofuel Enhancement Technology Spotlighted at National Conference: Chief Scientist to Discuss Recent Scientific Breakthroughs at NanoEnergy Conference Focusing on Commercialization of Technologies

Abstract:
VG Energy reports that Chief Scientist Dr. M. Karen Newell Rogers, has accepted an invitation as featured speaker at an upcoming NanoEnergy Summit hosted by the U.S. Department of Energy's National Renewable Energy Lab, the Colorado School of Mines and the biofuels industry. VGEnergy is a majority owned subsidiary of Viral Genetics (Pinksheets: VRAL).

VG Energy's Algal Biofuel Enhancement Technology Spotlighted at National Conference: Chief Scientist to Discuss Recent Scientific Breakthroughs at NanoEnergy Conference Focusing on Commercialization of Technologies

San Marino, CA | Posted on October 24th, 2011

The Nano Energy Summit is a gathering of world-renowned experts at the intersection of nanotechnology and energy, with a specific focus on the business, commercialization, and economic development potential of emerging technologies in the energy field.

The company's chief scientific advisor, Dr. M. Karen Newell Rogers will be discussing her work as it relates to the bio-fuels sector. Dr. Newell's research has brought critical insight into the cell's energy strategy. and the impact of that strategy on the immune response. By targeting metabolic disruption in tumor cells, she and her group have determined how to limit the cells' options for energy, rendering them unable to survive and/or unable to "hide" from the immune system. They have applied this technology to plants, and found a simple, profound method of increasing oil yield from algae and other plants, as an alternative energy source without the drawbacks of cost and waste.

"This profound original research by Dr. Rogers has been followed by developments at VG Energy that have direct applications in the algal biofuels sector," said Haig Kaledjian, VG Energy's CEO. "As we complete our march toward commercialization, we are pleased to have Dr. Rogers' work highlighted in such a high profile forum."

Copies of Dr. Rogers' presentation will be available on the company website following her presentation at the NanoEnergySummit, October 25 & 26, 2011, in Golden Colorado.

####

About VG Energy
VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc. Using its Metabolic Disruption Technology (MDT), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to developing biofuel and agricultural applications for the MDT platform. For more information, visit www.viralgenetics.com.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.’s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

For more information, please click here

Contacts:
Haig Keledjian
VG Energy
(626) 334-5310
Fax: 626-334-5324

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: